Supporting information

Synthesis of photolabile protecting group (PPG) protected uronic acid building blocks: Applications in carbohydrate synthesis with the assistance of continuous flow photoreactor

Varsha Tiwari,^{a#} Adesh Kumar Singh,^{a#} Priyanka Chaudhary,^a Peter H. Seeberger,^b Jeyakumar Kandasamy^a*

^aDepartment of Chemistry, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh-

221005, India. E-mail: jeyakumar.chy@iitbhu.ac.in

^bMax-Planck-Institute of Colloids and Interfaces, Department of Biomolecular Systems,

Am Mühlenberg 1, 14476 Potsdam, Germany

These authors contributed equally to this work

Table of Contents

S.No.	Content	Page No.
1	General information	2
2	(a)-General procedure for synthesis of uronic acid esters with 2-	2-5
	nitrobenzyl bromide (1a-10)	
	(b)- General procedure for synthesis of uronic acid esters (1m-	
	1n):	
3	Analytical data of 2-nitrobenzyl protected uronic acid esters(1a-	5 - 12
	10 and 4a-4d)	
4	Experimental procedure for deprotection of photolabile 2-	
	nitrobenzyl protecting group by using a continuous flow	
	photoreactor	13
5	Analytical data for various deprotected uronic acids (2a-20)	13- 18
6	Procedure for synthesis of D-Glucopyranuronic acid, 2,3,4-tris-O-	
	(phenylmethyl)-,2-nitrophenylmethylester,1-(2,2,2-	
	trichloroethanimidate) (1aa).	18
7	General procedure for glycosylation	19
8	Analytical data for various deprotected uronic acids (5a-5d)	19-21
10	Copy of ¹ H and ³ C-NMR spectra of intermediates and final	22
	compounds	

1. General Information

Starting materials were prepared using literature procedures or modified procedures. Solvents and chemicals were purchased from commercial sources and used without further purification. Thin layer chromatography was performed using pre-coated plates contained from E. Merck (TLC silica gel 60 F254). TLC plates were visualized by exposure to ultraviolet light (UV), and then further analyzed by charring in stain solution (5% H₂SO₄ in MeOH). The column chromatography was performed on silica gel (100-200 mesh) using a mixture of ethyl acetate/hexane and methanol/ethyl acetate as an eluent. The Continuous Flow Photoreactor was constructed with the help of M/s Lelesil innovative systems, Mumbai, India. The NMR spectra were recorded on BrukerAvance 500 MHz NMR spectrometer and Mass spectra were measured on Water's Quattro Micro V 4.1. All given ¹³C spectra are proton decoupled. The ¹H NMR and ¹³C NMRs of the monosaccharide primary alcohol and corresponding uronic acids were compared with literature reports.

2 (a)- General procedure for synthesis of uronic acid esters with 2-nitrobenzyl bromide: (1a-1o)



To a stirred solution of appropriate uronicacid (0.5 equiv.) in dry DMF, KHCO₃(4.0 equiv.), Bu_4NI (0.2 equiv.) and 2-nitrobenzyl bromide (3 equiv.) were added under argon atmosphere. The resulting mixture was stirred for 16 h at room temperature. After completion, the reaction mixture was filtered on celite. The filtrate was washed with water (2×50 mL) and dried over anhydrous sodium sulfate. The solvent was concentrated under reduced pressure to provide crude product which was purified by column chromatography on silica gel of 100-200 mesh size. Ethyl acetate/hexane was used as an eluent.

(b)- Preparation of uronic acid esters 1m and 1n:



Im preparation: The compound **AA** (3.0 g, 8.0 mmol) was stirred in dry pyridine (20 mL) in the presence of *tert*-butyldimethylsilyl chloride (1.81 g, 12.0 mmol) for overnight at room temperature. After completion, the reaction mixture was evaporated till dryness and dissolved in ethyl acetate. The resulting solution was washed with 0.1N HCl solution and brine solution. The crude was subjected for the column chromatography on silica (30% EtOAc: Hexane) to afford the primary TBDMS protected compound as a colorless syrup (3.13 g, 80% yield).

The TBDMS protected compound (1.0 g, 2.0 mmol) was dissolved in DMF (20 ml) at 0°C to which NaH (98 mg, 2 equiv.) followed by 4-bromobenzylbromide (562 mg, 1.1 eq.) was added. The reaction was stirred until TLC starting material got consumed. The reaction was quenched using water (5 mL) and diluted with ethyl acetate (20 mL). The ethyl acetate layer was washed with cold water and evaporated in vacuo. The crude product was further dried under high vacuum and dissolved in THF (20 ml) to which TBAF (3.0 equiv.) was added and stirred until starting material disappeared. The solvent was evaporated and the residue was dissolved in ethyl acetate and washed with brine. The organic layer was evaporated in vacuo and purified using column chromatography (20% EtOAc: Hexane) to afford the pure compound **AB** (723 mg, 70%) as yellowish oil.

To a vigorously stirred solution of **AB** (700 mg, 1.3 mmol) in DCM and H₂O was added TEMPO (0.3 eq) and 1-chloro-1, 2-benziodoxol-3(1H)-one (CBI) (909 mg, 2.5 eq). Stirring was allowed until TLC indicated complete conversion of the starting material to a lower running spot (~ 45 min). The reaction mixture was quenched by the addition of 10 ml Na₂S₂O₃ solution (10% in H₂O). The mixture was then extracted twice with EtOAc (10 ml)

and the combined organic layers were dried (Na₂SO₄), filtered and concentrated. The crude compound was purified by column chromatography using EtOAc/petroleum ether which afforded the pure glucuronic acid (560 mg, 78%). Further the glucuronic acid (279 mg, 0.5 mmol) was converted into corresponding 2-nitrobenzyl ester **1m** by using the general procedure (**2a**) mentioned above. The reaction provided **1m** as pale yellow viscous liquid (325 mg, 94%).

In preparation: The same procedure was adopted as above described for the preparation of **1m**. In the place of 4-bromobenzylbromide, 2-napthylmethylbromide (497mg, 1.1 eq.) was used. The compound **AC** was obtained as yellowish oil (736 mg, 75%). Corresponding glucuronic acid was obtained as pale yellow viscous compound (532 mg, 74%). The ester **1n** was obtained as pale yellow viscous liquid (309 mg, 93%).

((2R,3R,4S,5R,6R)-4,5-bis(benzyloxy)-3-((4-bromobenzyl)oxy)-6-methoxytetrahydro-2Hpyran-2-yl)methanol (AB):



Yellowish oil (667 mg, 60%); R_f value =0.4 in 20% EtOAc/ Hexane.IR: v_{max} (neat) 3320, 1099, 652 cm⁻¹. $[\alpha]_D^{24}$ = +45.0 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.40 (dd, J = 8.6, 1.9 Hz, 2H), 7.35–7.26 (m, 10H), 7.11 (d, J = 8.4 Hz, 2H), 4.98 (d, J = 11.0 Hz, 1H), 4.83–4.73 (m, 3H), 4.64 (d, J = 12.1 Hz, 1H), 4.57 (dd, J = 7.4, 3.9 Hz, 2H), 3.98 (t, J = 9.3 Hz, 1H), 3.76 (dd, J = 11.7, 2.4 Hz, 1H), 3.69–3.62 (m, 2H), 3.52–3.47 (m, 2H), 3.35 (s, 3H), 1.95 (s, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 138.8, 138.1, 137.3, 131.6, 129.5, 128.6, 128.5, 128.2, 128.0, 127.9, 127.7, 121.7, 98.2, 81.9, 80.1, 77.6, 75.8, 74.2, 73.4, 70.8, 61.8, 55.3. HRMS: Calc. for C₂₈H₃₆BrO₆[M+H]⁺: 543.1382, Obser. 543.1383

((2R,3R,4S,5R,6R)-4,5-bis(benzyloxy)-6-methoxy-3-(naphthalen-2-ylmethoxy)tetrahydro-2H-pyran-2-yl)methanol (AC):



Yellowish oil (685 mg, 65 %); R_f value =0.4 in 20% EtOAc/ Hexane.IR: v_{max} (neat) 3233, 1052, 631 cm⁻¹. $[\alpha]_D^{24}$ = +25.0 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.79–7.74 (m, 3H), 7.69 (s, 1H), 7.45–7.41 (m, 2H), 7.39 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.36–7.24 (m, 10H), 5.01 (dd, J = 11.1, 6.6 Hz, 2H), 4.85 (d, J = 11.0 Hz, 1H), 4.79 (dd, J = 11.7, 7.1 Hz, 2H), 4.65 (d, J = 12.1 Hz, 1H), 4.57 (d, J = 3.6 Hz, 1H), 4.04 (t, J = 9.3 Hz, 1H), 3.78 (dd, J = 11.5, 2.3 Hz, 1H), 3.72–3.66 (m, 2H), 3.58 (t, J = 9.3 Hz, 1H), 3.51 (dd, J = 9.6, 3.6 Hz, 1H), 3.35 (s, 3H), 1.89 (s, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 138.9, 138.2, 135.7, 133.4, 133.1, 128.6, 128.5, 128.3, 128.2, 128.1, 127.8, 127.7, 126.8, 126.26, 126.0, 126.0, 98.3, 82.1, 80.1, 77.6, 75.8, 75.2, 73.5, 70.9, 62.0, 55.3. HRMS: Calc. for C₃₂H₃₄O₆ [M+H]⁺: 515.2434, Obser. 515.2436

3. Analytical data of 2-nitrobenzyl protected uronic acid esters:

α-D-Glucopyranosiduronic acid, methyl-2,3,4-tris-*O*-(phenylmethyl)-2-nitrophenylmethyl ester(1a)



Pale yellow viscous liquid (289 mg, 94%), R_fvalue =0.7 in 30% EtOAc/ Hexane. IR: v_{max} (neat) 1742, 1425, 1120, 1090 cm⁻¹. $[\alpha]_D^{24}$ = -21.7 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.12 (dd, *J* = 5.9, 3.6 Hz, 1H), 7.53 (dd, *J* = 5.7, 3.5 Hz, 1H), 7.47–7.43 (m, 2H), 7.41–7.32 (m, 11H), 7.27 (dd, *J* = 4.8, 1.7 Hz, 2H), 7.21–7.19 (m, 2H), 5.60–5.53 (m, 2H), 5.02 (d, *J* = 10.9 Hz, 1H), 4.90–4.84 (m, 3H), 4.69 (t, *J* = 7.7 Hz, 2H), 4.60 (d, *J* = 11.0 Hz, 1H), 4.34 (d, *J* = 10.0 Hz, 1H), 4.07 (t, *J* = 9.3 Hz, 1H), 3.84 (t, *J* = 9.5 Hz, 1H), 3.64 (dd, *J* = 9.6, 3.5 Hz, 1H), 3.47 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 169.1, 147.1, 138.4, 137.9, 133.9, 131.5, 128.7, 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 128.1, 128.0, 127.7, 127.7, 125.0, 98.8, 81.5, 79.4, 79.3, 75.9, 75.0, 73.6, 70.3, 63.7, 55.7. HRMS: Calc. for C₃₅H₃₆NO₉[M+H]⁺:614.2390, Obser.614.2397.

α-D-Glucopyranosiduronic acid, methyl-2,3,4-tri-O-benzoyl-2-nitrophenylmethyl ester(1b)



Pale yellow viscous liquid (304 mg, 91%); R_f value =0.4 in 30% EtOAc/ Hexane.IR: v_{max} (neat) 1750, 1719, 1420, 1099 cm⁻¹.[α]_D²⁴= +93.0 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.16–8.10 (m, 2H), 8.00 (dd, J = 17.6, 9.4 Hz, 3H), 7.77 (d, J = 7.7 Hz, 1H), 7.70 (dd, J = 11.9, 5.7 Hz, 2H), 7.62–7.33 (m, 11H), 5.86 (t, J = 9.6 Hz, 1H), 5.73 (d, J = 6.8 Hz, 1H), 5.51–5.41 (m, 1H), 5.26 (tdd, J = 42.0, 9.9, 3.6 Hz, 2H), 5.00 (s, 1H), 4.60 (d, J = 10.1 Hz, 1H), 4.49 (d, J = 9.8 Hz, 1H), 4.22 (td, J = 9.5, 2.7 Hz, 1H), 3.52 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 169.0, 167.5, 166.8, 165.9, 147.4, 136.8, 134.1, 134.0, 133.6, 133.5, 133.4, 133.4, 131.3, 129.9, 129.9, 129.8, 129.4, 129.2, 129.0, 129.0, 128.9, 128.9, 128.4, 128.4, 128.4, 127.9, 125.2, 125.0, 97.5, 72.6, 71.0, 70.6, 64.1, 62.5, 56.0. HRMS: Calc. for $C_{35}H_{30}NO_{12}[M+H]^+$: 656.1768, Obser. 656.1772.

α-D-Glucopyranosiduronic acid, methyl 2, 3-di-O-acetyl-4-O-benzyl-2-nitrophenylmethyl ester (1c)



Pale yellow viscous liquid (240 mg, 93%); R_fvalue = 0.36 in 30% EtOAc/ Hexane. IR: v_{max} (neat) 1745, 1735, 1410, 1215, 1090 cm⁻¹.[α]_D²³= +44.5 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.15–8.13 (m, 1H), 7.54–7.48 (m, 3H), 7.29–7.27 (m, 4H), 7.20–7.18 (m, 2H), 5.65–5.56 (m, 3H), 5.00 (d, *J* = 3.5 Hz, 1H), 4.90 (dd, *J* = 10.2, 3.6 Hz, 1H), 4.59 (s, 2H), 4.40 (d, *J* = 9.9 Hz, 1H), 3.96 (t, *J* = 9.6 Hz, 1H), 3.48 (s, 3H), 2.09 (s, 3H), 1.98 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 170.3, 169.7, 168.4, 147.2, 137.3, 133.9, 131.4, 128.8, 128.5, 128.4, 127.9, 127.8, 125.1, 97.4, 77.6, 74.7, 71.3, 70.9, 69.9, 63.9, 55.7, 20.8, 20.7. HRMS: Calc. for C₂₅H₂₈NO₁₁ [M+H]⁺: 518.1662, Obser. 518.1668

α-D-Glucopyranosiduronic acid, methyl 2, 3-di-O-benzoyl-4-O-benzyl-2-nitrophenylmethyl ester (1d)



Yellow viscous liquid (312 mg, 95%); R_f value = 0.42 in 30% EtOAc/ Hexane. IR: v_{max} (neat) 1736, 1716, 1290, 1088, 1375 cm⁻¹[α]_D²⁴= +62.9 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.16 (dd, J = 8.0, 1.2 Hz, 1H), 8.01–7.98 (m, 4H), 7.60–7.48 (m, 5H), 7.40 (ddd, J = 12.9, 7.5, 5.3 Hz, 4H), 7.16–7.08 (m, 5H), 6.11 (t, J = 9.7 Hz, 1H), 5.65 (q, J = 15.2 Hz, 2H), 5.26–5.21 (m, 2H), 4.63–4.58 (m, 2H), 4.55 (d, J = 9.9 Hz, 1H), 4.21 (t, J = 9.5 Hz, 1H), 3.50 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 168.4, 165.8, 165.4, 147.0, 136.9, 133.9, 133.3, 133.2, 131.4, 129.8, 129.6, 129.3, 128.8, 128.7, 128.4, 128.3, 128.2, 127.9, 127.8, 125.0, 97.5, 77.4, 74.7, 71.8, 71.7, 70.0, 63.8, 55.8. HRMS: Calc. for C₃₅H₃₂NO₁₁ [M+H]⁺: 642.1975, Obser. 642.1970

α-D-Mannopyranosiduronic acid, methyl-2, 3, 4-tris-*O*-(phenylmethyl)-2-nitrophenylmethyl ester (1e)



Pale yellow viscous liquid (261 mg, 85%); R_f value = 0.5 in 20% EtOAc/ Hexane. IR: v_{max} (neat) 1752, 1445, 1135, 1075 cm⁻¹. $[\alpha]_D^{24}$ = +4.7 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.11–8.13 (m, 1H), 7.55-7.53 (m, 1H), 7.45–7.22 (m, 18H), 5.54 (q, *J* = 15.3 Hz, 2H), 4.94 (d, *J* = 2.9 Hz, 1H), 4.85-4.73 (m, 3H), 4.66-4.60 (m, 3H), 4.36–4.27 (m, 2H), 3.93 (dd, *J* = 8.1, 3.0 Hz, 1H), 3.80 (t, *J* = 3.1 Hz, 1H), 3.46 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 168.8, 147.1, 138.2, 138.0, 138.0, 133.8, 131.9, 128.5, 128.5, 128.3, 128.3, 127.8, 127.7, 127.6, 127.6, 125.0, 99.7, 78.7, 75.6, 74.5, 74.3, 72.9, 72.3, 72.0, 63.5, 55.6. HRMS: Calc. for C₃₅H₃₆NO₉ [M+H]⁺: 614.2390, Obser. 614.2386

α-D-Mannopyranosiduronic acid, methyl 2, 3, 4-tri-O-benzoyl-2-nitrophenylmethyl ester (1f)



Pale yellow solid (291 mg, 89%); M.P:133-135 \Box ; R_f value = 0.6 in 30% EtOAc/ Hexane. IR: v_{max}(neat) 1755, 1729, 1414, 1040 cm⁻¹. [α]_D²⁵= -60.2 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.14–8.08 (m, 4H), 7.99–7.97 (m, 2H), 7.87 (d, *J* = 8.1 Hz, 2H), 7.63–7.58 (m, 2H), 7.54–7.51 (m, 1H), 7.46–7.37 (m, 7H), 7.30–7.27 (m, 2H), 6.14 (t, *J* = 10.1 Hz, 1H), 5.95 (dd, *J* = 10.1, 3.3 Hz, 1H), 5.74 (dd, *J* = 3.1, 1.7 Hz, 1H), 5.03 (s, 1H), 4.75 (dd, *J* = 12.1, 2.4 Hz, 1H), 4.54 (dd, *J* = 12.1, 4.4 Hz, 1H), 4.47–4.39 (m, 1H), 3.57 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.2, 165.5, 165.4, 133.4, 133.4, 133.1, 133.0, 129.8, 129.8, 129.8, 129.7, 129.7, 129.3, 129.1, 129.0, 128.6, 128.47, 128.3, 98.7, 70.4, 70.0, 68.7, 66.9, 62.9, 55.6. HRMS: Calc. for C₃₅H₃₀NO₁₂ [M+H]⁺: 656.1768, Obser. 656.1770

β-D-Glucopyranosiduronic acid, phenyl 2, 3, 4-tri-*O*-benzoyl-1-thio-2-nitrophenylmethyl ester (1g)



Yellow viscous liquid (338 mg, 92%); R_f value = 0.48 in 30% EtOAc/ Hexane.IR: v_{max} (neat) 1748, 1718, 1422, 1140 cm⁻¹ .[α]_D²⁴= +18.7 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.07 (dd, J = 8.0, 1.5 Hz, 1H), 8.00– 7.98(m, 2H), 7.86–7.82 (m, 4H), 7.58–7.28 (m, 17H), 5.94 (t, J = 9.4 Hz, 1H), 5.73 (t, J = 9.7 Hz, 1H), 5.65–5.51 (m, 3H), 5.11 (d, J = 9.9 Hz, 1H), 4.51 (d, J= 9.8 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 165.9, 165.6, 165.0, 164.9, 147.2, 133.8, 133.7, 133.4, 133.4, 133.3, 131.0, 130.9, 129.9, 129.8, 129.8, 129.0, 128.8, 128.7, 128.6, 128.5, 128.4, 128.4, 128.3, 125.0, 86.4, 77.2, 76.6, 73.5, 70.0, 69.9, 64.3. HRMS: Calc. for C₄₀H₃₂NO₁₁S [M+H]⁺: 734.1696, Obser. 734.1699

β-D-Glucopyranosiduronic acid, phenyl-2, 3, 4-tris-*O*-(phenylmethyl)-1-thio-2nitrophenylmethyl ester (1h)



Pale yellow viscous liquid (311 mg, 90%); R_f value = 0.6 in 30% EtOAc/ Hexane. IR: v_{max} (neat) 1743, 1520, 1145, 1130 cm⁻¹. $[\alpha]_D^{24}$ = -2.9 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.18–8.10 (m, 1H), 7.56–7.20 (m, 22H), 5.53 (d, *J* = 5.3 Hz, 2H), 5.28 (d, *J* = 3.1 Hz, 1H), 4.94 (d, *J* = 10.8 Hz, 1H), 4.87–4.80 (m, 3H), 4.71 (d, *J* = 11.8 Hz, 1H), 4.61 (t, *J* = 10.4 Hz, 2H), 4.04 (t, *J* = 9.0 Hz, 1H), 3.84 (t, *J* = 9.2 Hz, 1H), 3.65 (dd, *J* = 9.1, 3.3 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 169.1, 147.0, 138.2, 137.7, 137.5, 133.9, 131.6, 128.6, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.1, 127.9, 127.9, 127.8, 127.7, 125.0, 97.8, 91.7, 80.7, 79.2, 78.9, 75.7, 74.9, 73.5, 70.6, 63.6. HRMS: Calc. for C₄₀H₃₈NO₈S [M+H]⁺: 692.2318, Obser. 692.2315

α-D-galactopyranosiduronic acid- 1, 2, 3, 4-Di-O-isopropylidene-2-nitrophenylmethyl ester (1i)



Pale yellow viscous liquid (180 mg, 88%); R_f value = 0.5 in 30% EtOAc/ Hexane. IR: v_{max} (neat) 1747, 1465, 1235 cm⁻¹. $[\alpha]_D^{24}$ = -62.4 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.13 (d, J = 8.2 Hz, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 5.75–5.67 (m, 11H), 5.31 (s, 1H), 4.68 (ddd, J = 28.6, 7.7, 2.3 Hz, 2H), 4.56 (d, J = 2.0 Hz, 1H), 4.41 (dd, J = 4.9, 2.6 Hz, 1H), 1.55 (s, 3H), 1.46 (s, 3H), 1.36 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 167.8, 147.2, 133.6, 132.0, 129.0, 128.6, 124.9, 110.0, 109.1, 96.5, 72.1, 70.7, 70.2, 68.6, 63.5, 25.9, 25.8, 24.7, 24.6. HRMS: Calc. for C₁₉H₂₄NO₉ [M+H]⁺: 410.1451, Obser. 410.1448





Pale yellow viscous liquid (347 mg, 93%); R_f value = 0.5 in 30% EtOAc/ Hexane.IR: v_{max} (neat) 1738, 1720, 1255, 1445 cm⁻¹[α]_D²⁴= +10.7 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.05 (dd, J = 8.0, 1.4 Hz, 1H), 7.99–7.97 (m, 2H), 7.84–7.80 (m, 4H), 7.52 (dd, J = 10.5, 4.2 Hz, 2H), 7.46–7.38 (m, 8H), 7.32–7.25 (m, 5H), 7.13 (d, J = 7.9 Hz, 2H), 5.93 (t, J = 9.4 Hz, 1H), 5.69 (t, J = 9.7 Hz, 1H), 5.58 (dd, J = 38.5, 14.8 Hz, 2H), 5.48 (t, J = 9.6 Hz, 1H), 5.04 (d, J = 9.9 Hz, 1H), 4.48 (d, J = 9.8 Hz, 1H), 2.35 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 165.9, 165.6, 165.0, 164.9, 147.2, 139.1, 134.4, 133.7, 133.4, 133.4, 133.3, 131.0, 129.8, 129.8, 129.8, 129.8, 129.8, 129.1, 129.0, 128.8, 128.6, 128.5, 128.4, 128.4, 128.3, 126.8, 125.0, 86.5, 76.6, 73.5, 70.0, 69.9, 64.2, 21.2. HRMS: Calc. for C₄₁H₃₄NO₁₁S [M+H]⁺: 748.1853, Obser. 748.1855

α-D-Glucopyranosiduronic acid, methyl-2-nitrophenylmethyl ester-2, 3-dibenzoate (1k)



Pale yellow viscous liquid (177 mg, 83%); R_f value = 0.5 in 40% EtOAc/ Hexane. IR: v_{max} (neat) 3250, 1756, 1718, 1360, 1180, 1080 cm⁻¹[α]_D²³= +134.5 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.13 (d, J = 8.2 Hz, 1H), 8.00–7.95 (m, 4H), 7.73–7.68 (m, 1H), 7.50 (dd, J = 4.5, 2.9 Hz, 3H), 7.36 (t, J = 7.5 Hz, 5H), 5.89–5.85 (m, 1H), 5.71 (q, J = 15.0 Hz, 2H), 5.25 (s, 2H), 4.49 (d, J = 9.9 Hz, 1H), 4.22 (t, J = 9.6 Hz, 1H), 3.49 (s, 3H), 3.47 (d, J = 0.9 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 168.9, 165.7, 162.5, 147.1, 133.9, 133.3, 133.2, 131.3, 129.7, 129.7, 129.5, 129.1, 128.8, 128.8, 128.7, 128.3, 128.2, 125.0, 97.4, 72.4, 71.0, 70.6, 70.5, 63.9, 55.8. HRMS: Calc. for C₂₈H₂₆NO₁₁ [M+H]⁺: 552.1506, Obser. 552.1501

(2S)-2-nitrobenzyl-2-((3aR, 6R, 6aR)-1-benzyl-6-(benzyloxy)-2-oxohexahydrofuro[3, 2-d]oxazol-5-yl)-2-hydroxyacetate (1l)



Pale yellow viscous liquid (214 mg, 80%); R_f value = 0.6 in 50% EtOAc/ Hexane. IR: v_{max} (neat) 3355, 1762, 1751, 1290, 1120, 1075 cm⁻¹. [α]_D²⁴= -48.6 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.10– 8.09(m, 1H), 7.52–7.45 (m, 3H), 7.41–7.38 (m, 3H), 7.29–7.27 (m, 4H), 7.24–7.22 (m, 2H), 7.12–7.10 (m, 2H), 6.22 (d, *J* = 5.5 Hz, 1H), 5.61 (dd, *J* = 80.6, 14.8 Hz, 2H), 4.85 (d, *J* = 3.6 Hz, 1H), 4.69 (d, *J* = 15.1 Hz, 1H), 4.32 (s, 2H), 4.20–4.17 (m, 2H), 4.10 (d, *J* = 5.6 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 166.0, 156.3, 147.3, 136.2, 134.9, 133.8, 131.1, 129.2, 129.1, 129.0, 128.6, 128.6, 128.3, 128.2, 127.6, 125.0, 101.0, 80.0, 79.9, 77.2, 72.4, 63.8, 63.7, 47.6. HRMS: Calc. for C₂₈H₂₇N₂O₉ [M+H]⁺: 535.1717, Obser. 535.1723

(2S,3S,4S,5R,6R)-2-nitrobenzyl-4,5-bis(benzyloxy)-3-(4-bromobenzyloxy)-6-methoxytetrahydro-2H-pyran-2-carboxylate (1m)



Pale yellow viscous liquid (325 mg, 94%); R_f value = 0.52 in 20% EtOAc/ Hexane. IR: v_{max} (neat)1730, 1520, 1250, 1070, 565 cm⁻¹ $[\alpha]_D^{24}$ = -7.8 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.17–8.06 (m, 1H), 7.50–7.46 (m, 3H), 7.38–7.28 (m, 12H), 7.02 (d, *J* = 8.1 Hz, 2H), 5.57 (q, *J* = 15.0 Hz, 2H), 4.99 (d, *J* = 10.9 Hz, 1H), 4.83–4.76 (m, 3H), 4.69–4.66 (m, 2H), 4.50 (d, *J* = 11.3 Hz, 1H), 4.29 (d, *J* = 10.0 Hz, 1H), 4.02 (t, *J* = 9.3 Hz, 1H), 3.77 (t, *J* = 9.5 Hz, 1H), 3.61 (dd, *J* = 9.6, 3.5 Hz, 1H), 3.46 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 169.0, 147.3, 138.4, 137.8, 136.9, 133.7, 131.3, 131.3, 129.2, 128.8, 128.7, 128.5, 128.4, 128.1, 128.1, 127.9, 127.7, 125.1, 121.5, 98.8, 81.3, 79.4, 79.3, 75.8, 74.1, 73.6, 70.1, 63.7, 55.7. HRMS: Calc. for $C_{35}H_{34}BrNO_9[M+H]^+$: 691.1417, Obser.691.1415

(2S,3S,4S,5R,6R)-2-nitrobenzyl-4,5-bis(benzyloxy)-6-methoxy-3-(naphthalen-2-ylmethoxy)-tetrahydro-2H-pyran-2-carboxylate (1n)



Pale yellow viscous liquid (309 mg, 93%); R_f value = 0.5 in 20% EtOAc/ Hexane. IR: v_{max} (neat) 1735, 1515, 1268, 1077 cm⁻¹. $[\alpha]_D^{25}$ = -8.9 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.03 (d, J = 7.9 Hz, 1H), 7.79–7.78 (m, 1H), 7.73–7.68 (m, 2H), 7.61 (s, 1H), 7.47– 7.25 (m, 17H), 5.50 (dd, J = 45.3, 15.2 Hz, 2H), 5.03 (dd, J = 11.0, 5.5 Hz, 2H), 4.87 (dd, J = 14.7, 11.6 Hz, 2H), 4.71 (dd, J = 21.0, 8.6 Hz, 3H), 4.36 (d, J = 9.9 Hz, 1H), 4.10 (t, J = 9.2 Hz, 1H), 3.88 (t, J = 9.5 Hz, 1H), 3.66 (dd, J = 9.6, 3.4 Hz, 1H), 3.47 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 169.0, 147.0, 138.4, 137.9, 135.3, 133.7, 133.1, 132.9, 131.4, 128.5, 128.4, 128.1, 128.1, 128.0, 128.0, 127.8, 127.7, 127.6, 126.4, 126.0, 125.9, 125.7, 124.9, 98.8, 81.5, 79.4, 79.3, 75.9, 75.1, 73.6, 70.3, 63.7, 55.7. HRMS: Calc. for C₃₉H₃₇NO₉ [M+H]⁺: 663.2468, Obser. 663.2471

β-D-Glucopyranosiduronic acid, phenyl-4-*O*-[6-methyl-2, 3, 4-*tris-O*-(phenylmethyl)-β-Dmannopyranuronosyl]-2, 3-*bis-O*-(phenylmethyl)-1-thio-2-nitrophenylmethyl ester (10)



Pale yellow viscous liquid (532 mg, 92%); R_f value = 0.5 in 30% EtOAc/ Hexane. IR: v_{max} (neat) 1755, 1745, 1395, 1285, 1076 cm⁻¹. [α]_D²⁴= +8.8 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.12-7.20 (m, 38H), 5.88 (s, 1H), 5.57 (dd, J = 42.3, 15.3 Hz, 2H), 4.96–4.47 (m, 15H), 4.06 (t, J = 9.3 Hz, 1H), 3.91-3.83 (m, 3H), 3.64–3.61 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 169.7, 168.9, 147.1, 138.5, 138.0, 138.0, 137.1, 137.0, 134.1, 131.7, 128.8, 128.7, 128.7, 128.6, 128.5, 128.2, 128.2, 128.0, 128.0, 128.0, 127.9, 127.9, 127.8, 127.8, 125.2, 102.5, 98.9, 81.2, 79.3, 77.4, 75.9, 75.3, 75.3, 74.1, 73.5, 73.0, 73.0, 72.3, 72.2, 71.1, 63.9. HRMS: Calc. for C₆₇H₆₃N₂O₁₆S [M+H]⁺: 1183.3898, Obser. 1183.3900

β-D-Glucopyranosiduronicacid, hexyl, 2, 3, 4-*tri-O*-benzyl-2-nitrophenylmethyl ester (4a)



Pale yellow solid (304 mg, 89%); M.P: 96-97 \Box ; R_f value = 0.7 in 30% EtOAc/ Hexane. β : α isomer (>20:1); IR: v_{max}(neat) 1751, 1517, 1305, 1125 cm⁻¹. [α]_D²⁴= -9.6 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.15–8.13 (m, 1H), 7.58–7.56 (m, 1H), 7.49–7.45 (m, 2H), 7.39–7.30 (m, 10H), 7.29–7.25 (m, 3H), 7.19 (dd, *J* = 6.8, 2.8 Hz, 2H), 5.63 (d, *J* = 15.3 Hz, 1H), 5.53 (d, *J* = 15.2 Hz, 1H), 4.97 (dd, *J* = 10.8, 9.6 Hz, 2H), 4.85 (dd, *J* = 16.8, 11.0 Hz, 2H), 4.76 (d, *J* = 10.9 Hz, 1H), 4.61 (d, *J* = 11.0 Hz, 1H), 4.53 (d, *J* = 7.7 Hz, 1H), 4.04–3.96 (m, 2H), 3.92 (t, *J* = 9.4 Hz, 1H), 3.73 (t, *J* = 9.1 Hz, 1H), 3.61-3.53 (m, 2H), 1.71–1.66 (m, 3H), 1.45–1.29 (m, 7H), 0.92 (dd, *J* = 9.5, 4.6 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 167.9, 147.1, 138.3, 138.2, 137.8, 133.8, 131.7, 128.6, 128.5, 128.4, 128.3, 128.1, 127.9, 127.8, 127.8, 127.7, 127.7, 125.0, 104.0, 83.9, 81.7, 78.9, 75.7, 74.9, 74.8, 74.5, 70.5, 63.6, 31.6, 29.6, 25.8, 22.5, 14.0. HRMS: Calc. for C₄₀H₄₆NO₉ [M+H]⁺: 684.3173, Obser. 684.3168

β-D-Glucopyranosiduronic acid-1, 2, 3, 4-*tetra-O*-benzyl-2-nitrophenylmethyl ester (4b)



Pale yellow powder. (293 mg, 85%); M.P: 124-126 \Box ; R_f value = 0.72 in 30% EtOAc/ Hexane. β : α isomer (>20:1); IR: v_{max}(neat) 1775, 1480, 1310, 1095 cm⁻¹. [α]_D²⁴= -22.9 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.15–8.13(m, 1H), 7.59–7.57 (m, 1H), 7.48–7.45 (m, 2H), 7.41–7.26 (m, 19H), 7.21–7.18 (m, 2H), 5.59 (dd, *J* = 49.7, 15.2 Hz, 2H), 5.02–4.93 (m, 3H), 4.84 (dd, *J* = 21.8, 11.0 Hz, 2H), 4.73 (dd, *J* = 22.2, 11.3 Hz, 2H), 4.64 (dd, *J* = 13.2, 9.3 Hz, 2H), 4.05 (d, *J* = 9.7 Hz, 1H), 3.96–3.93 (m, 1H), 3.74 (t, *J* = 9.0 Hz, 1H), 3.63 (dd, *J* = 9.0, 7.6 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 167.9, 147.2, 138.2, 138.1, 137.8, 137.0, 133.8, 131.6, 128.7, 128.6, 128.5, 128.4, 128.4, 128.4, 128.3, 128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 127.7, 125.0, 102.8, 83.9, 81.8, 78.9, 75.7, 74.9, 74.6, 71.4, 63.7. HRMS: Calc. for C₄₁H₄₀NO₉ [M+H]⁺: 690.2703, Obser. 690.2702

α-D-Glucopyranoside, methyl-6-*O*-[6-methyl-2,3,4-*tris-O*-(phenylmethyl)-D-glucopyranuronosyl]-2, 3, 4-*tris-O*-(phenylmethyl)-2-nitrophenylmethyl ester (4c)



Yellow solid (408 mg, 78%); M.P: 103-105 \Box ; R_f value = 0.5 in 30% EtOAc/ Hexane. β:α isomer (3:2); IR: v_{max}(neat) 1762, 1487, 1254, 1082 cm^{-1} . $[\alpha]_{D}^{24} = +12.1 \text{ [c } 0.1, \text{ CHCl}_{3}; \text{^{1}H NMR (500 MHz, CDCl}_{3})$ δ 8.12-8.09 (m, 1H), 7.45-7.39 (m, 2H), 7.38-7.24 (m, 29H), 7.18 (ddd, J = 7.7, 6.7, 1.7 Hz, 3H), 5.62-5.43(m, 2H), 5.03-4.92 (m, 3H),4.88-4.52 (m, 10H), 4.44 (t, J = 8.8 Hz, 1H), 4.17 (dd, J = 10.8, 1.7 Hz, 1H), 4.04-3.97 (m, 2H), 3.91-3.78 (m, 3H), 3.71-3.46 (m, 4H), 3.37 (d, J = 29.8 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 169.2, 167.7, 147.1, 138.8, 138.4, 138.3, 138.3, 138.2, 138.1, 138.1, 138.0, 137.8, 133.8, 133.7, 131.6, 131.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.4, 128.3, 128.2, 128.1, 128.0, 128.0, 127.9, 127.9, 127.9, 127.8, 127.7, 127.7, 127.7, 127.6, 127.6, 127.6, 127.5, 127.5, 125.0, 124.9, 104.1, 98.0, 98.0, 97.8, 84.0, 82.1, 81.9, 81.5, 81.0, 80.1, 79.8, 79.5, 79.3, 78.8, 77.9, 77.7, 77.2, 75.7, 75.7, 75.6, 75.0, 74.9, 74.9, 74.8, 74.6, 73.3, 72.7, 70.4, 70.3, 69.8, 68.9, 66.7, 63.6, 63.5, 55.2. HRMS: Calc. for C₆₂H₆₄NO₁₄ [M+H]⁺: 1046.4327, Obser. 1046.4329

D-Glucopyranosiduronic acid-1, 2, 3, 4-tetra-O-benzyl-2-nitrophenylmethyl ester (4d)



White solid. (165 mg, 52%); M.P: 123-125 \Box ; R_f value = 0.5 in 20% EtOAc/ Hexane. β : α isomer (3:1); IR: v_{max} (neat) 1775, 1480, 1310, 1095 cm⁻¹. [α]_D²⁴= -9.9 [c 0.1, CHCl₃]; ¹H NMR (500 MHz, CDCl₃) δ 8.15–8.14 (m, 1H), 7.60–7.20 (m, 24H), 5.66–5.53 (m, 2H), 5.03–4.95 (m, 3H), 4.89–4.71 (m, 4H), 4.65 (dd, J = 12.6, 9.4 Hz, 2H), 4.07 (d, J = 9.7 Hz, 1H), 3.97 (t, J = 9.3 Hz, 1H), 3.75 (t, J = 9.0 Hz, 1H), 3.65–3.62 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 169.1, 168.0, 147.2, 138.5, 138.3, 138.1, 137.9, 137.8, 137.0, 136.7, 133.8, 131.6, 128.7, 128.7, 128.6, 128.6, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 128.0, 128.0, 127.9, 127.8, 127.8, 127.7, 125.1, 102.8, 96.1, 83.9, 81.8, 81.5, 79.4, 79.4, 78.9, 75.9, 75.7, 75.1, 74.9, 74.6, 73.2, 71.4, 70.6, 69.6, 63.7. Calc. for C₄₁H₄₀NO₉ [M+H]⁺: 690.2703, Obser. 690.2705

4. Experimental procedure for deprotection of photolabile 2-nitrobenzyl protecting group by using a continuous flow photoreactor:

Approximately 0.005M solution of photolabile protected uronic acid building blocks were prepared in methanol and added to the reactor B. The solution was circulated with the help of peristaltic pump to the flexi coil with a flow rate 50 RPM which required approx. 3 minutes for completing one cycle. Total six cycles were repeated after which the solvent was evaporated and purified through column chromatography.

5. Analytical data for various deprotected uronic acids:

Methyl-2, 3, 4-tri-*O*-benzyl-α-D-glucopyranosiduronic acid (2a)¹



Colourless oily syrup (110mg, 92%); R_fvalue =0.6 in 50% EtOAc/ Hexane. IR: v_{max} (neat) 3482, 1712, 1120 cm⁻¹. [α]_D²⁴= +4.4 [c 0.1, CHCl₃]; ¹H NMR (500 MHz, DMSO-D₆) δ 7.40–7.22 (m, 16H), 4.91 (d, *J* = 3.4 Hz, 1H), 4.84 (d, *J* = 11.3 Hz, 1H), 4.75–4.66 (m, 4H), 4.58 (d, *J* = 11.0 Hz, 1H), 3.93 (d, *J* = 9.9 Hz, 1H), 3.79 (t, *J* = 9.3 Hz, 1H), 3.66–3.62 (m, 1H), 3.56 (dd, *J* = 9.6, 3.4 Hz, 1H), 3.34 (s, 3H).¹³C NMR (125 MHz, DMSO-D₆) δ 170.9, 139.0, 138.8, 138.6, 128.7, 128.6, 128.6, 128.1, 128.1, 128.0, 127.9, 127.9, 127.8, 127.8, 98.0, 80.8, 79.6, 75.0, 74.5, 72.0, 70.4, 55.3.HRMS: Calc. for C₂₈H₃₁O₇[M+H]⁺: 479.2070, Obser.479.2075.

Methyl-2, 3, 4-tri-*O*-benzoyl-α-D-glucopyranosiduronic acid (2b)



Colourless Oily syrup (116 mg, 89%); R_f value =0.5 in 60% EtOAc/ Hexane. IR: v_{max} (neat) 3545, 1718, 1710 cm⁻¹. [α]_D²⁴= +62.2 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.00–7.89 (m, 6H), 7.53 (q, *J* = 7.6 Hz, 2H), 7.46 (t, *J* = 7.4 Hz, 1H), 7.41-7.36 (m, 4H), 7.32 (t, *J* = 7.8 Hz, 2H), 6.20 (t, *J* = 9.8 Hz, 1H), 5.75 (t, *J* = 9.8 Hz, 1H), 5.37 (d, *J* = 3.6 Hz, 1H), 5.33 (dd, *J* = 10.1, 3.6 Hz, 1H), 4.66 (d, *J* = 10.1 Hz, 1H), 3.54 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 171.1, 165.7, 165.6, 165.4, 133.4, 133.4, 133.2, 129.9, 129.9, 129.7, 129.0, 128.8, 128.4, 128.4, 128.3, 97.4, 77.2, 71.4, 69.8, 68.0, 56.3.HRMS: Calc. for C₂₈H₂₅O₁₀[M+H]⁺: 521.1448, Obser. 521.1446

Methyl-2, 3-di-*O*-acetyl-4-benzyl-α-D-glucopyranosiduronic acid (2c)



Colourless oily syrup (87mg, 91 %); R_f value =0.5 in 50% EtOAc/Hexane. IR: v_{max} (neat) 3353, 1735, 1719, 1082 cm⁻¹. $[\alpha]_D^{24}$ = +53.6 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.34–7.29 (m, 7H), 7.26–7.25 (m, 2H), 5.59–5.55 (m, 1H), 4.99 (d, *J* = 3.5 Hz, 1H), 4.88 (dd, *J* = 10.2, 3.6 Hz, 1H), 4.65 (dd, *J* = 54.8, 11.1 Hz, 3H), 4.33 (d, J = 9.9 Hz, 1H), 3.89 (t, J = 9.5 Hz, 1H), 3.46 (s, 3H), 2.09 (s, 3H), 1.97 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 172.2, 170.3, 169.7, 137.2, 128.4, 128.0, 128.0, 97.3, 77.5, 74.7, 71.3, 70.8, 69.4, 55.8, 20.7, 20.7. HRMS: Calc. for C₁₈H₂₃O₉[M+H]⁺: 383.1342, Obser. 383.1343

Methyl-2, 3-di-O-benzoyl-4-benzyl-a-D-glucopyranosiduronic acid (2d)



Colourless oily liquid (119 mg, 94%); R_f value =0.6 in 50% EtOAc/ Hexane. IR: v_{max} (neat) 3260, 1715, 1708, 1124 cm⁻¹. [α]_D²⁴= +108.1 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.10–8.08 (m, 4H), 7.62 (dd, *J* = 15.5, 7.5 Hz, 2H), 7.49 (dt, *J* = 15.8, 7.9 Hz, 4H), 7.26 (s, 5H), 6.20 (t, *J* = 9.6 Hz, 1H), 5.35 (dt, *J* = 10.0, 3.6 Hz, 2H), 4.77 (dd, *J* = 38.0, 10.9 Hz, 2H), 4.61 (d, *J* = 9.9 Hz, 1H), 4.28 (t, *J*= 9.5 Hz, 1H), 3.58 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 173.6, 166.0, 165.6, 136.9, 133.5, 133.3, 129.9, 129.7, 129.4, 128.8, 128.4, 128.3, 128.2, 128.0, 97.5, 77.4, 77.3, 77.1, 76.9, 74.8, 71.9, 71.7, 69.8, 55.9.HRMS:Calc. for C₂₈H₂₇O₉[M+H]⁺: 507.1650, Obser.507.1648

Methyl-2, 3, 4-tri-*O*-benzyl-α-D-mannopyranosiduronic acid (2e)¹



Colourless oily syrup (105 mg, 88 %); R_f value =0.5 in50% EtOAc/PE; IR: v_{max} (neat) 3386, 1725, 1135 cm⁻¹. $[\alpha]_D^{23}$ =+15.0 (c, 1.2 in CHCl3); ¹H NMR (500 MHz, CDCl₃) δ 7.39–7.28 (m, 15H), 4.96 (s, 1H), 4.76 (dt, *J* = 24.4, 11.2 Hz, 4H), 4.64 (d, *J* = 3.9 Hz, 2H), 4.31–4.21 (m, 2H), 3.93–3.91 (m, 1H), 3.80–3.79 (m, 1H), 3.46 (d, *J* = 1.3 Hz, 3H).¹³C NMR (125 MHz, CDCl₃) δ 174.1, 138.1, 138.0, 137.7, 128.4, 128.1, 127.9, 127.8, 127.7, 127.6, 99.6, 78.5, 75.6, 74.5, 72.9, 72.4, 71.3, 55.7.HRMS: Calc. for C₂₈H₃₀O₇Na [M+Na]⁺: 501.1890, Obser.501.1893.

Methyl-2, 3, 4-tri-O-benzoyl-α-D-mannopyranosiduronic acid (2f)



Colorless oily syrup (121 mg, 93 %); R_f value =0.4 in 50% EtOAc/PE; IR: v_{max} (neat) 3558, 1712, 1708 cm⁻¹. [α]_D²⁴= -61.4 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.10 (dd, J = 8.2, 1.2 Hz, 2H), 7.98–7.97 (m, 2H), 7.87 (dd, J = 8.3, 1.2 Hz, 2H), 7.62 (t, J= 7.4 Hz, 1H), 7.54–7.45 (m, 4H), 7.39 (t, J = 7.7 Hz, 2H), 7.31 (t, J = 7.8 Hz, 2H), 6.05 (t, J = 9.5 Hz, 1H), 5.92 (dd, J = 9.6, 3.4 Hz, 1H), 5.69 (dd, J = 3.2, 2.5 Hz, 1H), 5.16 (d, J = 2.2 Hz, 1H), 4.69 (d, J = 9.4 Hz, 1H), 3.59 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 171.4, 165.5, 165.4, 165.3, 133.6, 133.4, 133.3, 129.9, 129.8, 129.7, 129.1, 129.0, 128.9, 128.6,

128.4, 128.3, 98.8, 69.8, 69.4, 69.3, 67.4, 56.2. HRMS: Calc. for $C_{28}H_{25}O_{10}$ [M+H]^{+ β}: 521.1448, Obser. 521.1455

Phenyl-2, 3, 4-tri-O-benzoyl-1-thio-β-D-glucopyranosyduronic acid (2g)



Colorless oily syrup (133 mg, 89%); R_f value = 0.53 in 50% EtOAc/PE; IR: v_{max} (neat) 3440, 1712, 1705 cm⁻¹. $[\alpha]_D^{24}$ = +23.3 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.99–7.97 (m, 2H), 7.92–7.91 (m, 2H), 7.84–7.83 (m, 2H), 7.56–7.28 (m, 14H), 5.92 (t, *J* = 9.3 Hz, 1H), 5.73 (t, *J* = 9.6 Hz, 1H), 5.54 (t, *J* = 9.6 Hz, 1H), 5.11 (d, *J* = 9.9 Hz, 1H), 4.39 (d, *J* = 9.8 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 170.4, 165.6, 165.1, 164.9, 133.3, 133.3, 133.2, 131.7, 129.9, 129.8, 129.8, 129.2, 129.0, 129.0, 128.8, 128.4, 128.4, 128.3, 128.2, 86.5, 73.8, 70.3, 69.9, 66.2. HRMS: Calc. for C₃₃H₂₇O₉S [M+H]⁺: 599.1376, Obser. 599.1377

Phenyl-2, 3, 4-tri-*O*-benzyl-1-thio-β-D-glucopyranosyduronic acid (2h)



Colorless oily syrup (132 mg, 95%); R_f value = 0.56 in 50% EtOAc/PE; IR: v_{max} (neat) 3280, 1730, 1095 cm⁻¹. $[\alpha]_D^{24}$ = -7.5 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.60–7.58 (m, 2H), 7.42–7.26 (m, 19H), 4.93 (d, *J* = 10.3 Hz, 1H), 4.88 (t, *J*= 7.8 Hz, 2H), 4.81–4.75 (m, 3H), 4.70 (d, *J* = 10.8 Hz, 1H), 4.01 (d, *J* = 9.3 Hz, 1H), 3.87 (t, *J* = 9.0 Hz, 1H), 3.77 (t, *J* = 8.6 Hz, 1H), 3.58 (dd, *J* = 9.6, 8.4 Hz, 1H)... ¹³C NMR (125 MHz, CDCl₃) δ 172.3, 138.0, 137.7, 137.3, 133.0, 132.3, 129.1, 128.5, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 88.1, 85.3, 80.2, 78.7, 77.5, 75.7, 75.4, 75.0. HRMS: Calc. for C₃₃H₃₃O₆S [M+H]⁺: 557.1998, Obser.557.2001

1, 2, 3, 4-Di-O-isopropylidene-α-D-galactopyranosiduronic acid (2i)



Colorless viscous liquid (62 mg, 90%); R_f value = 0.6 in 50% EtOAc/ Hexane.IR: v_{max} (neat) 3315, 1715 cm^{-1.1}H NMR (500 MHz, DMSO-d₆) δ 5.53 (d, J = 5.0 Hz, 1H), 4.65 (dd, J = 7.7, 2.5 Hz, 1H), 4.51 (dd, J = 7.7, 2.3 Hz, 1H), 4.40 (dd, J = 5.0, 2.5 Hz, 1H), 4.18 (d, J = 2.2 Hz, 1H), 1.43 (s, 3H), 1.32 (s, 3H), 1.28 (d, J = 3.3 Hz, 6H). ¹³C NMR (125 MHz, DMSO-d₆) δ 169.3, 109.1, 108.5, 96.2, 71.9, 70.5, 69.9, 67.7, 26.2, 26.1, 25.1, 24.8. HRMS: Calc. forC₁₂H₁₉O₇ [M+H]⁺: 275.1131, Obser. 275.1129

Tolyl-2, 3, 4-tri-*O*-benzoyl-1-thio-β-D-glucopyranosyduronic acid (2j)



White solid (147 mg, 96%); M.P: 195-197 \Box ; R_f value = 0.5 in 50% EtOAc/ Hexane. IR: v_{max} (neat) 3356, 1727, 1702 cm⁻¹[α]_D²⁴= +12.6 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 8.00–7.98 (m, 2H), 7.92 (dd, J = 8.4, 1.2 Hz, 2H), 7.85–7.83 (m, 2H), 7.57–7.53 (m, 1H), 7.52–7.48 (m, 1H), 7.47–7.45 (m, 3H), 7.43–7.40 (m, 2H), 7.35 (dd, J = 10.8, 4.9 Hz, 2H), 7.31–7.28 (m, 2H), 7.16 (d, J = 7.9 Hz, 2H), 5.93 (t, J = 9.3 Hz, 1H), 5.70 (t, J = 9.6 Hz, 1H), 5.51–5.47 (m, 1H), 5.05 (d, J = 9.9 Hz, 1H), 4.42 (d, J = 9.7 Hz, 1H), 2.37 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 170.1, 165.7, 165.2, 164.9, 139.1, 134.3, 133.4, 133.4, 133.3, 129.9, 129.9, 129.8, 129.1, 128.7, 128.6, 128.4, 128.4, 128.3, 127.0, 86.5, 75.9, 73.5, 70.0, 69.7, 21.2. HRMS: Calc. forC₃₄H₂₉O₉S [M+H]⁺: 613.1532, Obser. 613.1536

Methyl-2, 3-di-O-benzoyl-α-D-glucopyranosiduronic acid (2k)



Colorless oil (94 mg, 90%); R_f value = 0.55 in 50% EtOAc/PE; $[\alpha]_D^{24}$ = +4.4 [c 0.1, CHCl₃]; IR: v_{max} (neat) 3520, 3286, 1725, 1718, 1135 cm⁻¹ $[\alpha]_D^{24}$ = +151.7 [c 0.1, CHCl₃];¹H NMR (500 MHz, MeOD-d₄) δ 8.00–7.98 (m, 2H), 7.91 (dd, J = 6.0, 4.7 Hz, 2H), 7.54 (t, J = 7.4 Hz, 2H), 7.42-7.37 (m, 4H), 5.83–5.78 (m, 1H), 5.20 (dd, J = 8.8, 2.7 Hz, 2H), 4.28 (d, J = 10.0 Hz, 1H), 4.09 (t, J = 9.7 Hz, 1H), 3.49 (s, 3H).¹³C NMR (125 MHz, MeOD-d₄) δ 170.9, 166.1, 165.6, 133.2, 132.9, 129.6, 129.3, 129.2, 128.9, 128.1, 128.1, 97.5, 72.5, 71.7, 71.1, 69.8, 54.7. HRMS: Calc. for C₂₁H₂₁O₉ [M+H]⁺: 417.1186, Obser.416.1190

2-(1-benzyl-6-(benzyloxy)-2-oxohexahydrofuro[3, 2-d]oxazol-5-yl)-2-hydroxyacetic acid (2l)



Colorless oily syrup (54 mg, 79%); R_f value = 0.43 in 60% EtOAc/PE; IR: v_{max} (neat) 3306, 3120, 1711, 1302, 1135, 1070 cm⁻¹. $[\alpha]_D^{24}$ = -49.4 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.37–7.27 (m, 8H), 7.17 (t, *J* = 7.4 Hz, 3H), 6.14 (d, *J* = 5.0 Hz, 1H), 4.73 (s, 1H), 4.65 (d, *J* = 15.1 Hz, 1H), 4.40–4.31 (m, 2H), 4.17 (d, *J* = 3.3 Hz, 1H), 4.10 (s, 1H), 4.06– 4.04 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 169.3, 156.8, 136.3, 134.7, 129.2, 128.6, 128.6, 128.3, 128.2, 127.8, 101.2, 79.5, 77.4, 77.1, 76.9, 72.6, 64.2, 47.5.HRMS: Calc. for C₂₁H₂₂NO₇ [M+H]⁺: 400.1396, Obser. 400.1395

(2S,3S,4S,5R,6R)-4,5-bis(benzyloxy)-3-(4-bromobenzyloxy)-6-methoxytetrahydro-2H-pyran-2-carboxylic acid (2m)



Colorless viscous liquid (124 mg, 89%); R_f value = 0.20 in 50% EtOAc/PE. IR: v_{max} (neat) 3263, 1727, 1077, 585 cm⁻¹; $[\alpha]_D^{24}$ = -1.9 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.40–7.28 (m, 12H), 7.09 (d, *J* = 8.3 Hz, 2H), 4.99 (d, *J* = 11.0 Hz, 1H), 4.83–4.74 (m, 3H), 4.66 (t, *J* = 7.3 Hz, 2H), 4.58 (d, *J* = 11.1 Hz, 1H), 4.24 (d, *J* = 10.0 Hz, 1H), 4.02 (t, *J* = 9.3 Hz, 1H), 3.70 (t, *J* = 9.5 Hz, 1H), 3.60–3.58 (m, 1H), 3.44 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 173.9, 138.3, 137.7, 136.6, 131.4, 129.5, 128.5, 128.4, 128.2, 128.1, 127.9, 127.8, 121.7, 98.6, 81.3, 79.2, 79.1, 75.9, 74.3, 73.6, 69.6, 55.8. HRMS: Calc. for C₂₈H₂₉BrO₇ [M+H]⁺: 556.1097, Obser. 556.1094

(2S,3S,4S,5R,6R)-4,5-bis(benzyloxy)-6-methoxy-3-(naphthalen-2-ylmethoxy)tetrahydro-2Hpyran-2-carboxylic acid (2n)



Colorless viscous liquid (115 mg, 87%); R_f value = 0.20 in 50% EtOAc/PE; IR: v_{max} (neat) 3215, 1712, 1120 cm⁻¹. [α]_D²⁵= -6.2 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.79–7.74 (m, 3H), 7.66 (s, 1H), 7.47–7.44 (m, 2H), 7.39–7.32 (m, 11H), 4.99 (dd, *J* = 26.3, 10.9 Hz, 2H), 4.86–4.78 (m, 3H), 4.67 (t, *J* = 7.9 Hz, 2H), 4.29 (d, *J* = 10.1 Hz, 1H), 4.07 (t, *J* = 9.3 Hz, 1H), 3.78 (t, *J* = 9.5 Hz, 1H), 3.62 (dd, *J* = 9.6, 3.4 Hz, 1H), 3.44 (s, 3H).¹³C NMR (125 MHz, CDCl₃) δ 173.3, 138.4, 137.8, 134.9, 133.2, 133.0, 128.5, 128.4, 128.2, 128.1, 128.1, 127.9, 127.9, 127.7, 127.6, 126.8, 126.0, 125.9, 125.8, 98.6, 81.4, 79.2, 79.2, 75.9, 75.3, 73.6, 69.6, 55.8. HRMS: Calc. for C₃₂H₃₂O₇ [M+H]⁺: 528.2148, Obser. 528.2150

β-D-Glucopyranosiduronic acid, phenyl-2, 3-di-O-(benzyl)-1-thio-4-O-[2, 3, 4-tri-O-(benzyl)-β-D-glucopyranosiduronic acid] (20)



Colorless viscous liquid (207 mg, 91%); R_f value = 0.40 in 60% EtOAc/PE; IR: v_{max} (neat) 3540, 3325, 1722, 1710, 1130 cm⁻¹. $[\alpha]_D^{24}$ = +21.0 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.38–7.26 (m, 31H), 5.88 (s, 1H), 4.97–4.72 (m, 8H), 4.64–4.57 (m, 4H), 4.49 (t, *J* = 11.6 Hz, 2H), 4.06 (t, *J* = 9.3 Hz, 1H), 3.90 (d, *J* = 16.9 Hz, 2H), 3.80 (t, *J* = 9.5 Hz, 1H), 3.62 (dd, *J* = 10.0, 3.8 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 172.8, 169.6, 138.4, 137.9, 137.6, 137.0, 136.9, 128.6, 128.6, 128.4, 128.4, 128.2, 128.1, 128.1, 128.0, 127.9, 127.9, 127.7, 127.7, 102.3, 98.4, 81.0, 79.1, 79.0, 77.3, 75.7, 75.2, 75.0, 73.8, 73.4, 72.7, 72.7, 72.2, 72.0, 70.5. HRMS: Calc. for $C_{53}H_{53}O_{12}S$ [M+H]⁺: 913.3258, Obser. 913.3262

6. Procedure for synthesis of D-Glucopyranuronic acid, 2,3,4-tris-*O*-(phenylmethyl)-,2nitrophenylmethyl ester, 1-(2,2,2-trichloroethanimidate) (1aa):



To a stirred solution of thioglycosides, 1h (4g, 5.78 mmol) in 40 ml acetone-water (9:1; v/v) was added N-bromosuccinamide (3.09 g, 17.35 mmol) and stirred for 1hour at room temperature. After that he reaction was quenched with $NaHCO_3$ and evaporated to dryness. The residue was dissolved in ethyl acetate (150mL) and successively washed with sat.aq.NaHCO₃, water and brine. Organic layer was separated, dried using anhydrous sodium sulphate, evaporated in vacuo. The resulting residue was purified using silica gel column chromatography (2:1 hexane/ EtOAc) to give the corresponding hemiacetal 2.43 g (70%) as viscous oil. The hemiacetalwas dissolved in dry CH₂Cl₂ (20mL) and cooled to 0°C under argon atmosphere. DBU (0.2 ml,1.33mmol) andtrichloroacetonitrile (3.34 ml, 33.35 mmol)were added slowly and allowed to stir for 2h. After complete consumption of starting material, the reaction mixture was concentrated in vacuo and purified by silica gel column chromatography (30% EtOAc/ Hexane) with 1% added Et₃N to afford 2.23g (90%) as colourless foam; $\alpha:\beta$ isomer (15.31:1); R_f value =0.6 in 20% EtOAc/ Hexane. ¹H NMR (500 MHz, CDCl₃) δ 8.74 (s, 1H), 8.13 (dd, J = 7.7, 1.7 Hz, 1H), 7.54-7.46 (m, 3H), 7.37–7.33 (m, 10H), 7.30-7.28 (m, 3H), 7.23 (dd, J = 6.6, 3.0 Hz, 2H), 6.61 (d, J = 3.5 Hz, 1H), 5.56 (q, J =15.3 Hz, 2H), 5.03 (d, J = 10.9 Hz, 1H), 4.91 (t, J = 11.2 Hz, 2H), 4.78 (dd, J = 25.2, 11.7 Hz, 2H), 4.61 (dd, J = 29.5, 10.5 Hz, 2H), 4.16 (t, J = 9.3 Hz, 1H), 3.97–3.87 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 168.1, 161.0, 147.1, 138.2, 137.6, 137.6, 133.9, 131.4, 128.7, 128.5, 128.5, 128.4, 128.4, 128.1, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 125.0, 94.0, 91.0, 80.8, 78.8, 78.5, 75.8, 75.3, 73.1, 72.7, 63.8.

7. General procedure for Glycosylation:

7.a. Glycosylation through Glycosyl Imidate donor: Donor 1aa(0.5 mmol, 1equiv.) and acceptor (non- sugar 3 equiv. and sugar 1.2equiv.) were dissolved in freshly dried CH₂Cl₂ (8ml)and added to a flame dried round bottomed flask containing activated 4Å molecular sieves (300mg) under argon atmosphere. The reaction mixture was then cooled to 0°C to which the activator B(C₆F₅)₃ (10mol%) was added. The reaction was stirred further for 1.5 h allowing temperature to reach room temperature slowly.Quenching was done by the addition of Et₃N and filtered through Celite. The mixture was concentrated in vacuo and the resulting residue was purified by silica gel column chromatography to afford the desired glycosylated product (78-89%).

7.b.Glycosylation through thioglycoside donor: Typical NIS/TfOH-promoted glycosylation procedure: A mixture of glycosyl donor (**1h**)(0.5 mmol, 1equiv.), glycosyl acceptor (3 equiv.), and freshly activated molecular sieves ($4\Box$, 300 mg) in CH₂Cl₂(8.0 mL) was stirred under argon for 1 h. The solution was cooled to – 78 °C and NIS (1.1equiv.) and TfOH (10mol %) were added. The reaction was slowly allowed to reach 0 °C. Upon completion, the reaction was quenched by adding Et₃N. The solid was filtered off and the filtrate was washed with 1 M HCl, sat. NaHCO₃ solution, 10% Na₂S₂O₃and brine. The organic layer was separated, dried with anhydrous Na₂SO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel to afford the corresponding glycoside with 52% yield.

8. Analytical data for various deprotected uronic acids:

n-Hexyl-2, 3, 4-tri-O-benzyl-D-glucopyranosiduronic acid (5a)



White foam (123 mg, 90%); R_f value =0.5 in 50% EtOAc/ Hexane. IR: v_{max} (neat) 3105, 1716, 1132 cm⁻¹; β : α isomer (>20:1); $[\alpha]_D^{24}$ = -6.4 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.38–7.25 (m, 16H), 4.94 (dd, J = 17.6, 11.0 Hz, 2H), 4.81 (d, J = 10.2 Hz, 2H), 4.75 (d, J = 11.0 Hz, 1H), 4.67 (d, J = 10.7 Hz, 1H), 4.54 (d, J = 7.6 Hz, 1H), 4.01–3.96 (m, 2H), 3.85 (t, J= 9.1 Hz, 1H), 3.72 (t, J = 8.8 Hz, 1H), 3.59–3.52 (m, 2H), 1.70–1.64(m, 2H), 1.43–1.30 (m, 8H), 0.92–0.89 (m, 3H).¹³C NMR (125 MHz, CDCl₃) δ 172.9, 138.2, 138.1, 137.4, 128.4, 128.4, 128.1, 128.1, 127.9, 127.8, 127.7, 103.7, 83.5, 81.5, 78.8, 75.6, 75.0, 74.7, 74.0, 70.5, 31.6, 29.6, 25.7, 22.5, 14.0.HRMS: Calc. for C₃₃H₄₁O₇[M+H]⁺:549.2852, Obser. 549.2849

(Phenylmethyl)-2,3,4-tri-O-benzyl-D-glucopyranosiduronic acid (5b)



Viscous liquid. (130 mg, 94%); R_f value =0.6 in 50% EtOAc/ Hexane. IR: v_{max} (neat) 3215, 1705, 1145 cm⁻¹. β : α isomer (>20:1); $[\alpha]_D^{24}$ = -19.6 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.37-7.24 (m, 21H), 4.98 (d, *J* = 12.1 Hz, 1H), 4.90 (dd, *J* = 15.9, 10.9 Hz, 2H), 4.79 (t, *J* = 10.4 Hz, 2H), 4.68 (ddd, *J* = 18.2, 16.6, 9.2 Hz, 4H), 4.00 (d, *J* = 9.3 Hz, 1H), 3.88–3.84 (m, 1H), 3.70 (t, *J* = 8.7 Hz, 1H), 3.59 (t, *J* = 7.7 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 172.7, 138.2, 138.0, 137.4, 136.9, 128.5, 128.4, 128.4, 128.3, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7, 127.7, 102.5, 83.5, 81.6, 78.7, 75.6, 75.0, 74.8, 74.0, 71.5. HRMS: Calc. for C₃₄H₃₅O₇[M+H]⁺:555.2383, Obser. 555.2387

(2S,4S,5S,6R)-3,4,5-*tris*(benzyloxy)-6-(((2R,4S,5S,6S)-3,4,5-*tris*(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)methoxy)tetrahydro-2H-pyran-2-carboxylic acid (5c)



White solid (198 mg, 87%); M.P: 93-95 °C; R_f value =0.5 in 60% EtOAc/ Hexane. IR: v_{max} (neat) 3345, 1701, 1065 cm⁻¹. β : α isomer (3:2); $[\alpha]_D^{24}$ = +34.5 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.38–7.19 (m, 31H), 5.01–4.50 (m, 14H), 4.10–3.44 (m, 10H), 3.36 (d, J = 20.3 Hz, 3H).¹³C NMR (125 MHz, CDCl₃) δ 172.0, 170.4, 138.8, 138.7, 138.3, 138.2, 138.2, 138.1, 138.1, 138.0, 138.0, 137.5, 127.5, 128.4, 128.4, 128.3, 128.3, 128.3, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8, 127.8, 127.8, 127.7, 127.7, 127.6, 127.5, 103.5, 98.1, 98.0, 97.5, 96.1, 83.1, 82.0, 81.9, 81.2, 80.9, 80.1, 79.9, 79.3, 79.0, 78.7, 77.8, 77.7, 75.7, 75.7, 75.6, 75.3, 75.1, 75.0, 74.9, 74.8, 74.6, 73.9, 73.3, 72.6, 70.3, 69.9, 69.4, 69.0, 66.7, 55.3, 55.2.HRMS: Calc. for C₅₅H₅₉O₁₂[M+H]⁺:911.4007, Obser. 911.4012

(Phenylmethyl)-2, 3, 4-tri-O-benzyl-D-glucopyranosiduronic acid (5d)



Viscous liquid. (116 mg, 84%); R_f value = 0.6 in 50% EtOAc/ Hexane. IR: v_{max} (neat) 3217, 1708, 1085 cm⁻¹. β : α isomer (~3:1); $[\alpha]_D^{24}$ = +8.8 [c 0.1, CHCl₃];¹H NMR (500 MHz, CDCl₃) δ 7.43–7.26 (m, 20H), 5.00 (dd, J = 17.1, 11.4 Hz, 1H), 4.93–4.85 (m, 2H), 4.83–4.66 (m, 5H), 4.03 (d, J = 9.1 Hz, 1H), 3.87 (t, J = 8.9 Hz, 1H), 3.71 (t, J = 8.6 Hz, 1H), 3.61–3.58 (m, 1H).¹³C NMR (125 MHz, CDCl₃) δ 174.0, 173.0, 138.5, 138.2, 138.0, 137.8, 137.5, 136.96, 136.5, 128.5, 128.5, 128.5, 128.4, 128.4, 128.4, 128.4, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8, 127.7, 127.7, 102.6, 95.9, 83.6, 81.6, 81.4, 79.3, 79.1, 78.7, 75.9, 75.6, 75.3, 75.0, 74.8, 74.0, 73.2, 71.5, 69.9, 69.7. HRMS: Calc. for C₃₄H₃₅O₇ [M+H]⁺:555.2383, Obser. 555.2381

References:

1. D. J. Chambers, G. R. Evans and A. J. Fairbanks, *Tetrahedron* 2005, 61, 7184–7192.

7,414 7,414 7,1355 7,7359 7,7351 7,7351 7,7351 7,7321 7,7321 7,7321 7,7321 7,7325 7,7255 7,22557 7,22557 7,22557 7,22557 7,22557 7,25557 7,25557 7,25557 7,2



¹³C-NMR (125 MHz, CDCl₃) spectrum of compound AB



¹³C-NMR (125 MHz, CDCl₃) spectrum of compound AC











¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 1c



¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 1d





¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 1f

8.8083 8.8005 8.



78.132 78.132 8.132 8.132 8.137 7.455 7.455 7.457 7.457 7.7264 7.7264 7.7264 7.7264 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7265 7.7266 8.817 7.8657 9.8617<



¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 1h





¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 1j





8.109 8.109 8.106 8.107 8.106 8.107



All 25 All 25 All 26 All 27 All 28 All 28



¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 1m















¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 4c

(115)







$= \begin{array}{c} 8.005 \\ 7.005$





¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 2c





¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 2d





7,992 7,992 7,915





5.5537
5.5237
5.5237
5.5237
5.5237
4.637
4.4516
4.4906
4.4406
4.4406
4.4406
4.4406
4.4406
4.4406
4.4406
4.4406
4.4406
4.4406
4.4406
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206
4.4206





8000 7,2986 7,2910 7,2910 7,2903 7,2537 7,2197



7.372 7.363 7.307 7.293 7.293 7.293 7.293 7.2194 7.1194 7.





¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 2m



¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 2n

7,7,350 7,7,351 7,7,351 7,7,312 7,235 7,236 7,2357 7,2357 7,255 7,255 7,2557 7,2557 7,2557 7,2557 7,2557 7,2





¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 5a



7,3381 7,7357 7,7357 7,7357 7,7357 7,7357 7,7357 7,7357 7,7325 7,7325 7,7232 7,7233 7,



7,7,430 7,7391 7,331 7,335 7,335 7,335 7,335 7,335 7,331 7,335 7,235 7,2557 7,2557 7,2557 7,2557 7,2557 7,2557 7,2557 7,2557 7



¹³C-NMR (125 MHz, CDCl₃) spectrum of compound 5d